Peripheral Neuropathy Trial, Recruiting NCT06066801 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06066801
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have diabetes
  • People who have at least one sign of a bone infection (osteomyelitis), identified by either: a clinical test where a probe reaches the bone along with changes visible on a standard X-ray, OR signs of bone infection seen on a CT scan, MRI, or a specialised nuclear medicine scan (such as a white blood cell SPECT/CT or FDG-PET/CT scan)
  • People who have not taken any antibiotics in the 14 days before joining the trial

Who may not be able to join:

  • People who need urgent surgery
  • People who have severely reduced blood flow to a limb that cannot be improved with a procedure to restore blood flow
  • People who have taken antibiotics in the 15 days before the bone biopsy procedure
  • People whose bone infection is located in an area affected by a condition called Charcot foot (a type of bone and joint destruction linked to diabetes)
  • People who are not expected to live for at least one year
  • People who are unable to give informed consent or are unwilling to follow the research protocol
  • Women who are pregnant or breastfeeding
  • People who do not have French social insurance coverage
  • People receiving state medical aid (known as AME in France)
  • People who are detained, or who are under a legal guardianship or protection order

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Louis Potier, MD, PhD, Assistance Publique - Hôpitaux de Paris

Phone: 01 40 25 88 03

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 March 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

the remission of DFO

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov